Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis (Q26829604)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis	scientific article

Statements

scholarly article

1 reference

Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis (English)

1 reference

Pseudomonas aeruginosa

0 references

cystic fibrosis

0 references

author name string

Parkins

1

1 reference

Steven Vaughan

2

1 reference

John Lam

3

1 reference

language of work or name

1 reference

publication date

13 November 2013

1 reference

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

1 reference

7

1 reference

61-77

1 reference

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

7 April 2017

Microbiology of airway disease in a cohort of patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

7 April 2017

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

7 April 2017

Structural origins of aminoglycoside specificity for prokaryotic ribosomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

7 April 2017

Cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

7 April 2017

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

7 April 2017

Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Pseudomonas aeruginosa: resistance to the max

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Adherence with tobramycin inhaled solution and health care utilization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

A pipeline of therapies for cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Cystic fibrosis foundation: achieving the mission.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

High treatment burden in adults with cystic fibrosis: challenges to disease self-management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

A pilot study to compare tobramycin 80 mg injectable preparation with 300 mg solution for inhalation in cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Recent advances in cystic fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Safety assessment of hydroxypropyl methylcellulose as a food ingredient

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Aminoglycoside resistance in Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Formulation of aerosolized therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Macromolecular mechanisms of sputum inhibition of tobramycin activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Bacterial uptake of aminoglycoside antibiotics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Aminoglycoside-induced hearing loss in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 September 2017

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow(®) rapid and PARI LC Plus(®) nebulisers in cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Oxidative Stress Induction of the MexXY Multidrug Efflux Genes and Promotion of Aminoglycoside Resistance Development in Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Liposomal amikacin dry powder inhaler: effect of fines on in vitro performance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Distribution and elimination kinetics of intravenously and intramusculary administered tobramycin in man.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Gentamicin inactivation in purulent exudates: role of cell lysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

31 May 2018

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Update in cystic fibrosis 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Aminoglycoside ototoxicity susceptibility in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Shifting patterns of inhaled antibiotic use in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Case-control study of acute renal failure in patients with cystic fibrosis in the UK.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Inhaled tobramycin-associated hearing loss in an adolescent with renal failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Economic evaluation of Tobramycin nebuliser solution in cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Microbiological and immunologic considerations with aerosolized drug delivery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

The incidence of aminoglycoside antibiotic-induced hearing loss

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3836451

28 November 2018

Nebramycin, a new broad-spectrum antibiotic complex. 3. Isolation and chemical-physical properties

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment compliance in children and adults with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Convergence of interests in antibiotic-induced neuromuscular blockade

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The influence of postantibiotic effects and postantibiotic effects of sub-inhibitory concentrations of quinolones and aminoglycosides on phospholipase C of Pseudomonas aeruginosa

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nebramycin, a new broad-spectrum antibiotic complex. I. Detection and biosynthesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A multi-method assessment of treatment adherence for children with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Celiac syndrome; chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Barriers to treatment adherence for children with cystic fibrosis and asthma: what gets in the way?

1 reference

https://pubmed.ncbi.nlm.nih.gov/24324354

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4137/CCRPM.S10592

1 reference

https://api.fatcat.wiki/v0/release/qxvlfgie75a2ngddr4ijcg2oei

30 July 2022

based on heuristic

mapped directly with Wikidata item

release_qxvlfgie75a2ngddr4ijcg2oei

1 reference

https://api.fatcat.wiki/v0/release/qxvlfgie75a2ngddr4ijcg2oei

30 July 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

https://api.fatcat.wiki/v0/release/qxvlfgie75a2ngddr4ijcg2oei

30 July 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/qxvlfgie75a2ngddr4ijcg2oei

30 July 2022

based on heuristic

mapped directly with Wikidata item

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26829604&oldid=1956835098"